H. Noguchi

Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study

K. Fizazi, N. Tran, N. Matsubara, 2018, Japanese journal of clinical oncology.

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

T. Doi, T. Nishina, S. Takahashi, 2018, Investigational New Drugs.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

Mehrad Amin Eskandari, J. F. Tinto, A. Capucci, 2018, Indian heart journal.

Patient perceptions of psoriatic disease in Japan: Results from the Japanese subgroup of the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey

M. Kishimoto, H. Torii, H. Noguchi, 2022, The Journal of dermatology.

Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naïve prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial.

M. Oya, K. Fizazi, H. Kanayama, 2018 .

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors

T. Doi, T. Nishina, S. Takahashi, 2018, Investigational New Drugs.